DHH-B Capsules are made of a naturally derived compound known for its anxiolytic (anti-anxiety) properties and its ability to promote a calm, focused mental state. Often used as a safer alternative to traditional benzodiazepines, DHH-B supports cognitive function and stress resilience without the sedative effects or dependency risks. It’s ideal for individuals seeking improved mental clarity, reduced anxiety, and better emotional regulation.
The information provided on this page is for general informational purposes only and is not a substitute for professional medical advice. Always follow your RegenMD provider’s precise prescription and consult them directly with any questions or concerns. Not all patients qualify for every treatment—book a consultation to determine the best option for you.
DHH-B Capsules deliver Dihydrohonokiol-B; a naturally derived compound from magnolia bark extract prescribed for patients seeking calm focus, reduced anxiety, and improved stress resilience through a non-stimulant, non-habit-forming mechanism. It supports a clear, composed mental state without the sedation or cognitive impairment that limits conventional anxiolytics in daily use.
DHH-B targets GABA-A receptor subtypes with a selectivity profile that separates the anxiolytic benefit from the sedative liability. Where benzodiazepines produce broad GABA-A activation that impairs motor function and cognition alongside anxiety reduction, DHH-B's more targeted binding produces calm and emotional steadiness without these trade-offs. The cognitive clarity many patients experience follows naturally; reducing anxiety removes the neurological interference that disrupts concentration and working memory without requiring any stimulant activity.
RegenMD prescribes DHH-B Capsules in 30-count formulations with dosing established by your provider based on your stress profile and cognitive wellness goals.
DHH-B (Dihydrohonokiol-B) Capsules deliver a naturally derived compound from magnolia bark with documented anxiolytic and cognitive-supporting properties. DHH-B modulates GABA receptors to produce a calming, focused mental state without the sedation, cognitive blunting, or dependency risk associated with pharmaceutical anxiolytics. It is prescribed for patients seeking improved stress resilience, reduced anxiety, and sharper mental clarity through a non-habit-forming mechanism. Available in 30-count formulations.
Benzodiazepines bind broadly to GABA-A receptor subtypes and produce sedation, muscle relaxation, and anxiolytic effects simultaneously; with significant dependency risk from chronic use. DHH-B modulates GABA activity with greater receptor selectivity; producing the anxiolytic and calming properties of GABA potentiation without the sedative, motor-impairing, and dependency-inducing consequences of broad GABA-A activation. This selectivity allows DHH-B to reduce anxiety and promote calm focus without the cognitive or physical impairment that limits conventional anxiolytics in daytime use.
Anxiety generates neurological interference that actively impairs working memory, attention, and decision-making by consuming cognitive resources and disrupting the neurochemical environment in which focused thinking occurs. DHH-B addresses cognitive clarity not through stimulation but through the removal of anxiety-driven inhibition; by quieting the neurological noise that anxiety produces through selective GABA modulation, it restores the conditions under which cognitive function operates at its natural capacity. Patients typically report that the clarity and focus improvements are a direct consequence of reduced anxiety rather than a separate stimulant effect.
Your cart may be empty now, but let us help you fill it up with amazing products.